Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
26/04/2025
Reuters survey: The South African Reserve Bank will maintain the repurchase rate at 7.50% in May, with the next rate cut expected to take place in July or September.
Latest
5 m ago
Nomura: Maintains the rating of Rivian Automotive (RIVN.US) and adjusts it from reduce to hold, with a target price adjustment from $11.00 to $10.00.
6 m ago
On Friday, the offshore Chinese yuan against the US dollar was reported at 7.2885 at the New York closing, up 15 points from Thursday's New York closing. The overall intraday trading range was between 7.2986 and 7.2816 yuan.
6 m ago
The Federal Reserve released a financial stability report, indicating risks related to asset valuation pressures.
7 m ago
Park Ntl (PRK.US): The first quarter financial report of 2025 achieved a revenue of 1.301 billion US dollars, compared to 1.218 billion US dollars in the previous period, with an expected value of 1.304 billion US dollars. Earnings per share were $2.57, compared to $2.15 in the previous period, with an expected value of $2.15.
7 m ago
Jefferies Investment Bank: Maintain Summit Therapeutics (SMMT.US) rating, adjusted from buy to buy rating, with target price adjusted from $31.00 to $44.00.
See all latest